Medication Preapproval Use Conspiracy

The FDA and Big Pharma have formed a criminal partnership to push untested, dangerous drugs onto an unsuspecting public, and the evidence is hiding in plain sight.

They lied to get emergency use authorization for drugs that were never properly vetted, and when independent voices started asking questions, the machine came down hard on them. The FDA has been faulted for inappropriate collaboration with drug companies before approval — that is not a fringe accusation, that is documented. This is how Big Pharma bought FDA approval for useless drugs, and the corruption runs so deep that the regulators and the manufacturers are now functionally the same entity. Follow the money and you will find it every time. Robert F. Kennedy Jr. has been sounding the alarm for years: why is Big Pharma going after our children? Because children are the longest-term customers, and a sick population is a profitable population.

Look at the specific cases they don't want you to examine too closely. The FDA approved Merck's RSV shot despite alarming infant trial data. There is a warning the mainstream press buried: the FDA approved a drug that makes mothers go suicidal. These are not isolated regulatory failures — this is a pattern, and a pattern has a purpose. The war against peptides, the suppression of alternatives, the endless revolving door between agency and industry — it all points toward the same conclusion. What we are witnessing is evidence of conspiracy to commit mass murder by the pharma manufacturers, carried out in bureaucratic daylight, dressed up as public health.

This theory claims that the FDA and pharmaceutical companies are engaged in a secret coordinated conspiracy to approve dangerous, undertested drugs — using the clinical trial system as theater to manufacture public trust, while deliberately engineering harmful health outcomes to maintain population control. The specific evidence marshaled includes the user-fee funding structure of the FDA, a study about drug approval evidence standards, and the approval history of the antidepressant Viibryd.

The factual record collapses the most explosive claims before the reasoning failures even need to be addressed. Start with the "Harvard investigation" allegation: the 73% figure cited does not come from a Harvard-led investigation. It comes from a two-year investigation conducted by The Lever and the McGraw Center for Business Journalism; the team included a postdoctoral fellow at Harvard, but that is the extent of the Harvard connection. More importantly, what the investigation actually found is being systematically misrepresented. The four criteria researchers applied — a control group, replication across two well-conducted trials, blinding of participants and investigators, and clinical endpoints like symptom relief or extended survival — are the FDA's own stated ideal standards, and only 28% of approved drugs met all four. That is a genuine and serious finding about evidentiary standards, discussed openly by researchers, journalists, and regulators alike. But the investigation itself does not claim the drugs were "dangerous" or that approval was fraudulent; it argues that expedited pathways and surrogate endpoints have weakened the bar for proving a drug works. More than half of drug approvals were based on preliminary data rather than sound evidence that patients had fewer symptoms, improved function, or lived longer. This is a documented, debated institutional problem — not a secret. It has been the subject of peer-reviewed literature, congressional testimony, and mainstream journalism, none of which is what a functioning conspiracy looks like.

The PDUFA user-fee structure is also real and publicly known, but the theory badly distorts how it operates. The Prescription Drug User Fee Act was passed by Congress in 1992 and allows the FDA to collect fees from drug manufacturers to fund the new drug approval process. The FDA is required by law to spend user fee funds only on specified activities; for human prescription drugs, those funds can only be used for monitoring of research, review of drug applications, and post-market safety activities. The fee structure funds additional reviewers rather than replacing existing oversight, and the FDA retains full authority to reject applications regardless of fees paid. The theory states "over 40% of the FDA's drug review budget comes from industry fees," but this figure is actually a significant undercount — today, user fees account for roughly 77% of the FDA's budget for reviewing new drugs. The theory uses a lower number to make the entanglement sound more marginal and hidden; the real number is far higher, and it has been publicly reported, debated in Congress, and subject to reauthorization votes every five years. PDUFA has been renewed by Congress in 1997, 2002, 2007, 2012, 2017, and 2022. None of this is hidden. The fact that critics have real concerns about it — some have long argued that relying heavily on industry fees creates pressure to approve drugs faster, potentially at the expense of safety, and data does show that as review times shortened, the amount of clinical evidence required for approval also declined — makes it a legitimate policy debate, not evidence of collusion.

The Viibryd example, presented as a smoking gun, dissolves on inspection. Vilazodone was administered to a total of 369 healthy volunteers and 1,163 patients with depression but failed to demonstrate significant efficacy against placebo initially in Phase II, partly because placebo effects were as great as drug effects; however, a subsequent Phase III clinical trial demonstrated statistical significance against placebo. This is precisely how the phased trial system is supposed to work: early-phase failure does not terminate development if later, larger, better-controlled trials succeed. Approval for Viibryd was based on two pivotal, Phase 3, eight-week, multicenter, randomized, double-blind, placebo-controlled studies in adult outpatients with major depressive disorder, in which vilazodone demonstrated superiority over placebo. The FDA's own review documents, which are publicly accessible, confirm this directly: the efficacy of vilazodone was evaluated in two Phase 3 clinical efficacy trials, and the individual study results for the five Phase 2 studies were explicitly not considered supportive of efficacy claims — meaning the agency fully acknowledged those earlier failures and based approval on the Phase 3 data. This is documentary evidence of the system working as designed, not evidence of a cover-up.

The theory's deepest structural problem is unfalsifiability: every piece of evidence that the process is open, documented, and publicly contested gets reinterpreted as proof of how sophisticated the deception is. Real institutional failures — and they do exist — get absorbed into an all-explaining framework. There are genuine concerns worth taking seriously here. A 2022 study found that almost 70% of FDA-approved drugs for rare diseases later required safety-related labeling changes, signaling risks not recognized at the time of approval, with about 15% of those updates involving severe side effects. The FDA is also preparing to reduce the default number of clinical trials it will require to approve new drugs, a shift that independent experts warn may increase risks. These are real, citable, publicly documented concerns — and they are being actively fought over by researchers, patient advocates, Congress, and the press. That is what accountability looks like. Converting them into proof of a conspiracy to deliberately harm populations for control requires not evidence but a prior commitment to the conclusion, and it actively crowds out the kind of specific, structural reform pressure that could actually improve drug safety.